Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 11/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4546572 | 0.85 | NFATC1 (0.42) | NFATC1GSK3BDYRK1ACYP19A1MAPT | |
| SCHEMBL28573158 | 0.81 | CYP19A1 (0.45) | CYP19A1MAPTCDC7CDK2SLC22A12 | |
| SCHEMBL2127959 | 0.80 | SLC22A12 (0.44) | CYP19A1MAPTCDC7CDK2RAPGEF4 | |
| SCHEMBL23084376 | 0.78 | SLC6A2 (0.50) | CYP19A1MAPTCDC7CDK2RAPGEF4 | |
| SCHEMBL18821952 | 0.77 | CYP19A1 (0.40) | CYP19A1MAPTCDC7CDK2RAPGEF4 | |
| SCHEMBL27647386 | 0.77 | RAPGEF4 (0.37) | CYP19A1MAPTCDC7CDK2RAPGEF4 | |
| SCHEMBL19250470 | 0.76 | JAK2 (0.36) | NFATC1GSK3BDYRK1ACDK2 | |
| SCHEMBL15341744 | 0.75 | HTR2A (0.44) | NFATC1GSK3BDYRK1ARAPGEF4HTR2A | |
| SCHEMBL29509135 | 0.74 | MAPT (0.68) | NFATC1GSK3BDYRK1ACYP19A1MAPT | |
| SCHEMBL255050 | 0.74 | MAPT (0.68) | NFATC1GSK3BDYRK1ACYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV INDIANA TRUSTEES (US) | 2023-04-20 | — | — | US | disclosed |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230026056-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042337-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | NFATC1 2433/4885GSK3B 518/4885DYRK1A 1313/4885 |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | NFATC1 1129/4885GSK3B 155/4885DYRK1A 1574/4885 |
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | NFATC1 2411/4885GSK3B 1960/4885DYRK1A 3333/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NFATC1 9/4885GSK3B 1721/4885DYRK1A 4017/4885 |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | NFATC1 1437/4885GSK3B 1359/4885DYRK1A 4786/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | NFATC1 1129/4885GSK3B 155/4885DYRK1A 1574/4885 |
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | BRIX1, REL, CNKSR1 | NFATC1 547/4885GSK3B 2618/4885DYRK1A 1517/4885 |
| US-20230026056-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | NFATC1 3119/4885GSK3B 4524/4885DYRK1A 4770/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | NFATC1 3119/4885GSK3B 4524/4885DYRK1A 4770/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | NFATC1 1077/4885GSK3B 168/4885DYRK1A 3072/4885 |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | NAMPT, NNT, NAPRT | NFATC1 1437/4885GSK3B 1359/4885DYRK1A 4786/4885 |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | NFATC1 3119/4885GSK3B 4524/4885DYRK1A 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.